TLDR: AmplifAI, a leading AI-powered platform for contact center performance, has successfully closed a $33.7 million Series B funding round, comprising both equity and a credit facility. Led by CVS Health Ventures, with continued support from LiveOak Ventures and Dallas Venture Partners, this capital infusion will accelerate the company’s mission to enhance human and AI agent performance, drive product innovation in generative AI, and expand its market presence in critical sectors like healthcare and financial services.
Plano, Texas – AmplifAI, a pioneering AI-powered platform dedicated to transforming enterprise contact center performance and customer experience, announced today the successful closure of a $33.7 million Series B funding round. This significant investment, which includes both equity and a credit facility, is set to propel the company’s advancements in integrating human teams with sophisticated AI agents to deliver best-in-class customer interactions at scale.
The funding round was spearheaded by CVS Health Ventures, underscoring AmplifAI’s growing relevance in sectors where efficient customer interactions directly impact accessibility and affordability, such as healthcare. Existing investors LiveOak Ventures and Dallas Venture Partners also participated, signaling their continued confidence in AmplifAI’s growth trajectory and its innovative approach to AI-driven workforce optimization.
This latest capital injection brings AmplifAI’s total funding to approximately $52.2 million to date, nearly doubling its previous Series A round of $18.5 million closed in October 2021. The $33.7 million total provides flexible capital for both immediate growth initiatives and long-term research and development.
The strategic deployment of these funds will focus on several key areas:
Product Innovation: A significant portion of the investment will accelerate platform enhancements, with a strong emphasis on generative AI capabilities. This includes developing advanced tools for real-time coaching, automated quality assurance (QA), and unified data analytics across various communication channels such as voice, chat, and surveys. The goal is to refine hybrid human-AI workflows, aiming to reduce agent handle times, boost conversion rates, and elevate customer satisfaction scores.
Market Expansion: AmplifAI plans to deepen its penetration into high-growth verticals. While aligning with CVS Health Ventures’ expertise, the company will particularly focus on expanding its footprint in healthcare, financial services, technology, and retail sectors.
Operational Scaling: The funding will also support the scaling of operations, including hiring new talent and bolstering infrastructure to support the more than 10,000 customer experience (CX) teams already leveraging the AmplifAI platform.
Also Read:
- Confido Health Secures $10 Million Series A to Advance AI Voice Agents in Healthcare
- Assort Health Secures $76 Million Series B to Advance AI-Powered Patient Communication in Healthcare
AmplifAI’s platform utilizes AI and agent performance data to optimize contact center efficiency, addressing the dual imperatives of cost reduction and enhanced personalization that enterprises face today. The company’s vision is to empower high-performing human teams and AI agents, driving the future of customer experience through intelligent automation and actionable insights.
